Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating in a report released on Wednesday. The analysts noted that the move was a valuation call.
Separately, Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $33.00.
Shares of Accelerate Diagnostics (AXDX) opened at $30.00 on Wednesday. Accelerate Diagnostics has a fifty-two week low of $16.75 and a fifty-two week high of $30.45.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXA purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at $8,441,000. Russell Investments Group Ltd. purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at $7,616,000. Artal Group S.A. purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at $5,470,000. Oaktop Capital Management II L.P. purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at $4,239,000. Finally, Kornitzer Capital Management Inc. KS increased its holdings in shares of Accelerate Diagnostics by 37.3% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 530,219 shares of the medical research company’s stock valued at $11,903,000 after acquiring an additional 144,055 shares during the period. Institutional investors own 47.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/12/13/btig-research-lowers-accelerate-diagnostics-axdx-to-neutral.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.